SCHEMBL3292136

SCHEMBL3292136

CN(CCN)CCCN(C)CCN1C(=O)c2cccc3cccc(c23)C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.68
HEXA P06865 6/20 0.66
HEXB P07686 6/20 0.66
POLB P06746 4/20 0.63
NR1I2 O75469 1/20 0.63
AHR P35869 1/20 0.63
RAD52 P43351 1/20 0.63
RCE1 Q9Y256 1/20 0.63
FTO Q9C0B1 2/20 0.55
CYP2D6 P10635 1/20 0.55
KMT2A Q03164 3/20 0.50
SIRT1 Q96EB6 2/20 0.50
MEN1 O00255 2/20 0.50
OGA O60502 1/20 0.50
CYP3A4 P08684 1/20 0.50
NFKB1 P19838 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CYP1B1 Q16678 1/20 0.50
CYP1A2 P05177 1/20 0.50
TNNI3 P19429 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28976570 0.96 HEXA (0.71) LCKHEXAHEXBPOLBNR1I2
SCHEMBL3290709 0.95 HEXA (0.69) LCKHEXAHEXBPOLBNR1I2
SCHEMBL8620098 0.93 HEXA (0.75) LCKHEXAHEXBPOLBNR1I2
SCHEMBL28976576 0.89 HEXA (0.82) LCKHEXAHEXBPOLBNR1I2
SCHEMBL9261482 0.88 HEXA (0.74) LCKHEXAHEXBPOLBNR1I2
SCHEMBL10396110 0.86 POLB (0.83) LCKHEXAHEXBPOLBNR1I2
SCHEMBL12672650 0.85 LCK (0.65) LCKHEXAHEXBPOLBNR1I2
SCHEMBL12660257 0.84 HEXA (0.61) LCKHEXAHEXBPOLBNR1I2
SCHEMBL14463932 0.84 LCK (0.64) LCKHEXAHEXBPOLBNR1I2
SCHEMBL12672841 0.83 LCK (0.66) LCKHEXAHEXBPOLBNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331355-A1 Substituted Quinolines for the Treatment of Cancer CRYSTAX PHARMACEUTICALS, S.L. (ES) 2010-12-30 US disclosed
US-7728000-B2 Substituted quinolines for the treatment of cancer CRYSTAX PHARMACEUTICALS (ES) 2010-06-01 US disclosed
US-20070105784-A1 Substituted quinolines for the treatment of cancer CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105784-A1 Substituted quinolines for the treatment of cancer TOP2B, NQO2, SNRPD2 LCK 2513/4885HEXA 1139/4885HEXB 953/4885
US-20100331355-A1 Substituted Quinolines for the Treatment of Cancer TOP2B, TOP1, TOP2A LCK 2718/4885HEXA 1337/4885HEXB 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.